Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

CRSP - CRISPR Therapeutics AG Financial... | Finranks

Home

/

CRSP

C

CRISPR Therapeutics AG (CRSP)

NGM – Real Time Price. Currency in USD

53.73

-0.34 (-0.63%)

Market open: Aug 12, 2026, 10:17 AM EDT

53.80

-0.27 (-0.50%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Total Assets

Total Liabilities

Stockholders Equity

Total Debt

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

4M

37M

371M

1M

Cost of goods sold

-233M

-130M

-150M

-134M

Gross Profit

-229M

-92M

221M

-133M

Operating expenses (excl. COGS)

-339M

-374M

-444M

-540M

Operating Income

-568M

-467M

-223M

-673M

Non-operating income, total

-10M

104M

72M

23M

Pretax income

-578M

-363M

-151M

-651M

Equity in earnings

0

0

0

0

Taxes

-4M

-4M

-3M

325K

Non-controlling/minority interest

0

0

0

0

After tax other income/expense

0

0

0

0

Net income before discontinued operations

-582M

-366M

-154M

-650M

Discontinued operations

0

0

0

0

Net income

-582M

-366M

-154M

-650M

Dilution adjustment

0

0

0

0

Preferred dividends

0

0

0

0

Name

2025

2024

2023

2022

Total assets

2.27B+1.0%

2.24B+0.6%

2.23B-0.6%

2.24B

Total current assets

1.99B

1.94B

1.91B

1.85B

Total non-current assets

280M

305M

321M

390M

Total liabilities

343M+10.8%

310M-10.6%

347M-5.7%

368M

Total current liabilities

149M

88M

109M

121M

Total non-current liabilities

194M

222M

238M

246M

Total equity

1.92B

1.93B

1.88B

1.88B

Total liabilities & shareholders' equities

2.27B

2.24B

2.23B

2.24B

Total debt

207M-7.6%

224M-6.3%

239M-2.2%

244M

Name

2025

2024

2023

2022

Cash from operating activities

-345M

-143M

-260M

-496M

Cash from investing activities

-32M

-280M

375M

-259M

Cash from financing activities

426M

332M

63M

39M

Free cash flow

-346M-139.1%

-145M+46.4%

-270M+49.4%

-533M